Richard Wooster

Richard Wooster

Director/Board Member at IKENA ONCOLOGY, INC.

Net worth: - $ as of 31/03/2024

59 year
Health Technology
Consumer Services

Profile

Richard Wooster is an Independent Director at Ikena Oncology, Inc. since 2022.
He was the Chief Scientific Officer at Translate Bio, Inc. from 2019 to 2021.
Prior to that, he was the Vice President & Unit Head-Oncology at GlaxoSmithKline LLC from 2006 to 2013.
He was also the Chief Scientific Officer & President-R&D at Tarveda Therapeutics, Inc. from 2015 to 2019.
He worked as a Senior Investigator at Wellcome Trust Sanger Institute.
Dr. Wooster completed his undergraduate and doctorate degrees from the University of Dundee.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
08/09/2023 0 ( -.--% ) - $ 31/03/2024

Richard Wooster active positions

CompaniesPositionStart
IKENA ONCOLOGY, INC. Director/Board Member 21/01/2022
All active positions of Richard Wooster

Former positions of Richard Wooster

CompaniesPositionEnd
TRANSLATE BIO, INC. Chief Tech/Sci/R&D Officer 14/09/2021
President 01/03/2015
Corporate Officer/Principal 01/01/2013
Corporate Officer/Principal -
See the detail of Richard Wooster's experience

Training of Richard Wooster

University Of Dundee Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Richard Wooster's experience

Connections

77

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
IKENA ONCOLOGY, INC.

Health Technology

Private companies4

Health Technology

Health Technology

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Richard Wooster